Broadcast Date: 
  • Time: 

AAVs have become the number one vehicle for delivering a transgene to a patient; however, the pace of their development as gene therapies is stymied by a lack of reliable and high throughput analytical methods. By applying advances in size exclusion chromatography, it is becoming possible to quickly perform potency indicating assays that check aggregation, measure vector fill percentages, and facilitate in-depth characterization of process and product related impurities. 

In this webinar, Mateusz Imiolek and Lavelay Kizekai will introduce techniques for AAV characterization that make use of low adsorption, high efficiency SEC column technology and the coupling of advanced detectors for multi attribute measurements. A fast turnaround of results for several clinically relevant AAV serotypes has been prioritized to give new capabilities for process and formulation development projects.

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelists.

Mateusz Imiolek
Mateusz Imiolek, PhD
Waters Corporation,
Geneva, Switzerland
Lavelay Kizekai
Lavelay Kizekai
Waters Corporation,
Milford, Massachusetts

Waters logo

Comments are closed.